Abstract
Background Seasonal malaria chemoprevention (SMC) is recommended for disease control in settings with moderate to high Plasmodium falciparum transmission and currently depends on administration of sulfadoxine-pyrimethamine with amodiaquine. However, poor regimenadherence and the increasedfrequencyof sulfadoxine-pyrimethamine resistant parasite mutations may threaten SMC’s effectiveness. We need guidance to de-risk the development of drug compounds for malaria prevention.
Methods We combined an individual-based malaria transmission model that has explicit parasite growth with drug pharmacokinetic/pharmacodynamic models. We modelled SMC drug attributes for several possible modes-of-action, linked to their potential public health impact. Global sensitivity analyses identified trade-offs between drug elimination half-life, maximum killing effect, and SMC coverage, and optimisation identified minimum requirements to maximise malaria burden reductions.
Findings Model predictions show that preventing infection for the entire period between SMC cycles is more important than drug curative efficacy for clinical disease effectiveness outcomes, but similarly important for impact on prevalence. When four SMC cycles are deployed to children under five years with high levels of coverage (69% of children receiving all cycles), drug candidates require a duration of protection half-life of >23 days (elimination half-life >10 days) to achieve >75% clinical incidence and severe disease reductions (measured over the intervention period in the target population, compared with no intervention across a range of modelled scenarios). High coverage is critical to achieve these targets, requiring >60% of children received all SMC cycles and >90% of children at least one cycle regardless of the drug’s duration.
Interpretation While efficacy is crucial for malaria prevalence reductions, chemoprevention development should select drug candidates for their duration of protection to maximise burden reductions, with the duration half-life determiningcycle timing. Explicitlydesigning or selectingdrug properties to increase communityuptake is paramount.
Funding Bill & Melinda Gates Foundation and the Swiss National Science Foundation.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the Bill & Melinda Gates Foundation (INV-002562 to MAP). TM and MAP acknowledge support from the Swiss National Science Foundation (SNF Professorship PP00P3_170702 and PP00P3_203450 to MAP). AMT is an employee of Medicines for Malaria Venture (MMV).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All code and datasets are available on GitHub
https://github.com/lydiab-mayer/modelling-smc-drug-properties/tree/v1.0.0
